Table 1 Clinical trials of radiotherapy combined with immunotherapy
From: Advances in radiotherapy and immunity in hepatocellular carcinoma
Clinical trial identification(study name) | Phase | Disease | Type of radiotherapy | Type of immunotherapy | Treatment design | Estimated enrollment | Primary outcome measures |
|---|---|---|---|---|---|---|---|
NCT04913480 | II | HCC | SBRT | Durvalumab (anti-PD-L1) | SBRT → durvalumab | 37 | Progression-free survival (PFS) |
NCT05225116 | I | HCC | Radiotherapy | Sintilimab (anti-PD-1) | (Sintilimab + lenvatinib) → radiotherapy | 20 | Safety (number of participants with adverse events) |
NCT05185531 | I | HCC | SBRT | Tislelizumab (anti-PD-1) | Neoadjuvant tislelizumab + SBRT | 20 | ORR, pCR (pathological complete response), pPR (pathological partial response), MPR (major pathologic response) |
NCT04169399 | II | HCC | SBRT | Toripalimab (anti-PD-1) | Toripalimab + sBRT | 30 | PFS |
NCT04709380 | III | Advanced HCC | Radiotherapy | Toripalimab (anti-PD-1) | (Radiotherapy + toripalimab) vs sorafenib | 85 | Time to progression (TTP) |
NCT03482102 | II | HCC | Radiation | Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4) | Tremelimumab + durvalumab + radiation | 70 | Overall response rate (ORR) |
NCT03316872 | II | HCC | SBRT | Pembrolizumab (anti-PD-1) | Pembrolizumab + SBRT | 30 | Overall response rate (ORR) |
NCT05530785 | II | Non-resectable HCC | Radiotherapy | Sintilimab (anti-PD-1) | radiotherapy + (sintilimab and bevacizumab biosimilar) | 35 | Overall response rate (ORR) |
NCT04104074 | I | HCC | Radiotherapy | Sintilimab (anti-PD-1) | Radiotherapy + sintilimab | 20 | Safety (number of participants with adverse events) |
NCT03857815 | II | HCC | SBRT | Sintilimab (anti-PD-1) | SBRT + sintilimab | 30 | PFS |
NCT04857684 | I | HCC | SBRT | Atezolizumab (anti-PD-L1) | SBRT + atezolizumab + bevacizumab | 20 | Safety (number of participants with adverse events) |
NCT03203304 | I | HCC | SBRT | Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4) | SBRT + nivolumab OR SBRT + nivolumab + ipilimumab | 14 | Safety (number of participants with adverse events) |
NCT05096715 | I | Non-resectable HCC | SBRT | Atezolizumab (anti-PD-L1) | SBRT + atezolizumab + bevacizumab | 20 | Dose limiting toxicity rate |
NCT04611165 | II | Advanced HCC | EBRT (External beam radiotherapy) | Nivolumab (anti-PD-1) | Nivolumab → EBRT | 50 | PFS |
NCT04850157 | II | HCC with portal vein tumor thrombus (PVTT) | Intensity modulated radiation therapy (IMRT) | Tislelizumab (anti-PD-1) | Tislelizumab + IMRT | 30 | Relapse-free survival ( RFS) |
NCT04167293 | II | HCC | SBRT | Sintilimab (anti-PD-1) | SBRT or SBRT + sintilimab | 116 | PFS |
NCT05010434 | II | Recurrent HCC | Radiotherapy | Sintilimab (anti-PD-1) | Radiotherapy + sintilimab + bevacizumab | 46 | Overall response rate (ORR) |
NCT05366829 | II | HCC | Radiotherapy | Toripalimab (anti-PD-1) | Radiotherapy + tislelizumab | 35 | Safety (number of participants with adverse events) |
NCT04430452 | II | Advanced HCC | Hypofractionated radiotherapy (HPT) | Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4) | HPT + durvalumab ± tremelimumab | 30 | Overall response rate (ORR) |
NCT03380130 | II | HCC | Selective internal radiation therapy (SIRT) using Y-90-loaded microspheres | Nivolumab (anti-PD-1) | SIRT + nivolumab | 41 | Incidence of adverse event |
NCT05625893 | II | HCC | proton beam therapy (PBT) | Atezolizumab (anti-PD-L1) | PBT → (atezolizumab + bevacizumab) | 63 | Incidence of adverse event, PFS |
NCT04547452 | II | Stage IV HCC | SBRT | Sintilimab (anti-PD-1) | SBRT + sintilimab OR sintilimab | 84 | PFS |
NCT05377034 | II | Locally Advanced HCC | SIRT | Atezolizumab (anti-PD-L1) | SIRT + atezolizumab + bevacizumab | 176 | Best overall response rate (BORR) |
NCT05701488 | I | HCC | SIRT | Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4) | Durvalumab + tremelimumab vs durvalumab + tremelimumab + SIRT | 20 | Safety (number of participants with adverse events) |
NCT02837029 | I | Stage IIIA—IVB HCC | SIRT | Nivolumab (anti-PD-1) | SIRT + nivolumab | 27 | Maximum tolerated dose (MTD), overall response rate (ORR) |
NCT04785287 | I/II | Metastatic liver carcinoma | SBRT | Nivolumab (anti-PD-1) and BMS986218 (anti-CTLA-4) | SBRT + BMS986218 ± nivolumab | 13 | Incidence of adverse event |